iShares MSCI Intl Multifactor ETF
INTF - ETF AI Analysis
Top Page
iShares MSCI Intl Multifactor ETF (INTF)
INTF, the iShares MSCI Intl Multifactor ETF, earns a solid overall rating thanks to several high-quality global leaders like Novartis, HSBC, AstraZeneca, and ABB, which bring strong financial performance, positive earnings outlooks, and generally supportive technical trends to the portfolio. Some holdings such as Roche and BHP introduce caution due to valuation concerns and short-term bearish or overbought signals, and the fund’s heavy tilt toward large international financial and healthcare names means investors should be aware of sector concentration risk.
INTF vs. SPDR S&P 500 ETF (SPY)
- AUM
- 3.74B
- Region
- Developed Markets
- Expense Ratio
- 0.16%
- Beta
- 0.75
- Issuer
- iShares
- Inception Date
- Apr 28, 2015
- Dividend Yield
- 3.00%
- Asset Class
- Equity
- Index Tracked
- STOXX International Equity Factor
INTF Summary
INTF is an ETF that follows the STOXX International Equity Factor index, giving you a broad mix of stocks from countries like Japan, the UK, and Europe. It uses a “multifactor” approach, picking companies based on value, quality, momentum, and size to try to improve returns while spreading risk. Well-known holdings include ASML Holding and Nestlé. Someone might invest in INTF to diversify beyond the U.S. market and gain long-term growth potential from many different industries. A key risk is that international stocks can go up and down with global markets and currency swings.
How much will it cost me?
INTF has an annual expense ratio of 0.16%, which means you’ll pay about $1.60 per year for every $1,000 invested. This cost is lower than the average stock ETF because it’s a passively managed fund that tracks a rules-based multifactor index rather than relying on expensive active stock-picking.
What would affect this ETF?
INTF could benefit if developed markets outside the U.S. grow steadily, global trade remains strong, and sectors like technology, health care, and financials continue to perform well, supporting major holdings such as ASML, Novartis, and Royal Bank of Canada. On the downside, slower economic growth abroad, rising interest rates that pressure banks, or regulatory changes affecting large international companies could weigh on the ETF’s broad mix of sectors and its multifactor strategy.
INTF Top 10 Holdings
INTF leans heavily on a mix of European health care and financial giants, with ASML and Novartis doing much of the heavy lifting. ASML has been rising over the year, giving the fund a tech-powered boost, while Novartis and Roche add steady, defensive strength from the pharma side. On the banking front, Royal Bank of Canada and Mitsubishi UFJ are generally supportive, though HSBC has been lagging lately and BHP’s recent slump in materials has been a mild drag. Overall, it’s a developed-markets ex-U.S. story with diversified sector exposure but a clear tilt toward Europe’s blue chips.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Novartis AG | 2.22% | $82.92M | CHF 245.70B | 26.78% | 80Outperform | |
| ASML Holding NV | 2.20% | $81.89M | EUR 525.92B | 51.88% | 76Outperform | |
| Roche Holding AG | ― | ― | ― | ― | 73Outperform | |
| Royal Bank Of Canada | ― | ― | ― | ― | 75Outperform | |
| HSBC Holdings | 1.08% | $40.15M | GBP 231.91B | 20.93% | 80Outperform | |
| Mitsubishi UFJ Financial Group | 1.04% | $38.70M | JPY 39.37T | 41.84% | 76Outperform | |
| Nestlé SA | 1.00% | $37.33M | CHF 222.68B | 8.18% | 71Outperform | |
| AstraZeneca | ― | ― | ― | ― | 80Outperform | |
| BHP Group Ltd | 0.91% | $33.87M | AUD 303.03B | 35.84% | 68Neutral | |
| ABB Ltd | ― | ― | ― | ― | 78Outperform |
INTF Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For INTF, the sentiment is Positive. The current price of 41.47 is above the 20-day moving average (MA) of 41.34, below the 50-day MA of 41.70, and above the 200-day MA of 40.88, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 50.22 is Neutral, neither overbought nor oversold. The STOCH value of 67.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INTF.
INTF Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $41.47 | $43.00(3.69% Upside) | $3.74B | 0.16% | 64Neutral | |
| $44.18 | $47.55(7.63% Upside) | $6.69B | 0.40% | 69Neutral | |
| $46.54 | $55.22(18.65% Upside) | $6.05B | 0.25% | 65Neutral | |
| $57.32 | $70.77(23.46% Upside) | $4.17B | 0.25% | 71Outperform | |
| $50.17 | $62.95(25.47% Upside) | $4.12B | 0.30% | 69Neutral | |
| $76.32 | $91.09(19.35% Upside) | $3.00B | 0.43% | 62Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| INTF | iShares MSCI Intl Multifactor ETF | 41.47 | 6.16 | 17.45% | |
| LVHI | Legg Mason International Low Volatility High Dividend ETF | 44.18 | 9.49 | 27.36% | |
| GSIE | Goldman Sachs ActiveBeta International Equity ETF | 46.53 | 6.41 | 15.99% | |
| IDMO | Invesco S&P International Developed Momentum ETF | 57.32 | 5.65 | 10.93% | |
| IMTM | iShares MSCI Intl Momentum Factor ETF | 50.17 | 4.63 | 10.15% | |
| PXF | Invesco FTSE RAFI Developed Markets ex-U.S. ETF | 76.32 | 15.80 | 26.12% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
